Wolverine Trading
CLDX icon

Wolverine Trading’s Celldex Therapeutics CLDX Stock Holding History

Wolverine Trading’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,058
Closed -$201K – 4596
2023
Q4 		$201K Buy
+5,058
New +$149K ﹤0.01% 3877
2019
Q3 		– Sell
-10,852
Closed -$25.1K – 4398
2019
Q2 		$29K Sell
10,852
-10,065
-48% -$34.2K ﹤0.01% 4262
2019
Q1 		$103K Buy
+20,917
New +$110K ﹤0.01% 4133
2018
Q1 		– Sell
-1,489
Closed -$63K – 5144
2017
Q4 		$63K Sell
1,489
-519
-26% -$22.2K ﹤0.01% 4564
2017
Q3 		$86K Sell
2,008
-600
-23% -$22.5K ﹤0.01% 4113
2017
Q2 		$98K Buy
2,608
+206
+9% +$9.11K ﹤0.01% 3899
2017
Q1 		$130K Sell
2,402
-821
-25% -$42.8K ﹤0.01% 3732
2016
Q4 		$171K Buy
+3,223
New +$183K ﹤0.01% 3842

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wolverine Trading's CLDX Position: Q1 2024 in Review

Wolverine Trading sold out of Celldex Therapeutics (CLDX) in Q1 2024, closing a stake of 5,058 shares — an estimated $201K sold.

Wolverine Trading first reported a position in CLDX in Q4 2016 and held it in 8 quarters. The position peaked at $201K in Q4 2023. 197 funds tracked by Wall St. Rank hold CLDX as of Q1 2024.

  • Wolverine Trading reported no remaining Celldex Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Wolverine Trading sold 5,058 Celldex Therapeutics shares in Q1 2024, an estimated $201K.
  • Wolverine Trading first reported a position in Celldex Therapeutics in Q4 2016 and held it in 8 quarters.
  • Wolverine Trading's Celldex Therapeutics position peaked at $201K in Q4 2023.
  • 197 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2024.

Based on Wolverine Trading's 13F filing for Q1 2024, filed 15 May 2024.